Abbott Laboratories ABT

$97.50 +0.81 (0.84%)

Valuation

Market cap
168,712,336,000
Revenue TTM
$44,328,000,000
Net income TTM
$6,524,000,000
PE ratio
18.38
Forward PE
17.51
Profit margin
14.72%
Debt to equity
0.63

Trading

Volume
8,709,900
Avg volume
8,498,294
Day's range
$95.06 – $97.59
Shares out
1,730,383,000
Stochastic %K
26%
Beta
0.59
Analysts
Strong Sell
Price target
$121.44

Price

Company profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic chol...

Show more

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

Industry
Medical Devices
Sector
Healthcare
Phone
224 667 6100
Website
https://www.abbott.com
Address
100 Abbott Park Road, Abbott Park, United States

Latest news

Stocktwits

KryptonResearch14 Oct 3, 12:29 PM
$ABT Rothschild & Co Redburn moved Abbott to Buy on Friday, lifting its target to 127 from 119 (per Benzinga, via MarketBeat). That is about 30 percent upside from Friday's close near 97.50. What stands out is how far the tape and the Street have drifted apart. The stock is down about 22 percent this year and still sits below its 50-day average. Meanwhile 21 analysts rate it a Buy, with an average target of 119.80. The validator is the Q3 print on Oct 21: consensus looks for adjusted EPS of 1.43 against 1.30 a year ago, and the company guides 5.45 to 5.60 for fiscal 2026. Tracking this into the Oct 21 print.
0 replies
DBRGLong Oct 2, 6:59 PM
$ABT Wow! Is it really a green day for us?!? I must be dreaming! 🥂 Many more to come as we grind our way back towards $130+. Have a great weekend all 😎
0 replies
ripster47 Oct 2, 1:41 PM
$ABT | Rothschild Redburn Upgrades Abbott Labs to Buy with $127 PT on Medical Devices Strength and Diagnostics Growth Rothschild Redburn stays bullish as Medical Devices momentum and Exact Sciences integration drive stronger growth outlook. 🔹 Follow @tenet_research for more analyst insights on other tickers.
0 replies
1212JM Oct 2, 12:59 AM
$ABT if the 5 year chart was a gif it would be this
0 replies
Wolfieteet Oct 2, 12:03 AM
$ABT great Q 3 earnings. Watch.
1 replies
DBRGLong Oct 1, 10:31 PM
$ABT some day in the future, despite what will be the ongoing focus on the AI hype, companies with real earnings & solid cash flows will begin to matter to the market again. We will look back on ABT being under $100 as an absolute gift, & almost hard to believe. Until then, let's keep collecting the reliable dividend, just as ABT shareholders have since 1924, & for well over a hundred years now.
0 replies
william2012 Oct 1, 8:34 PM
$ABT don't buy it. The price action dropped before earnings, 99% must go lower.👍👍
0 replies
knowinvest Oct 1, 8:01 PM
$ABT breaks the support of 98 and drifts lower towards ER, hope ER number will reverse the downwards trend
0 replies